Furthermore, only two studies reported outcomes in BC patients, with no significant interstudy heterogeneity, and the pooled HR (95% CI) in the fixed effects model indicated a significant increased risk of a poor prognosis for patients with RASSF1A methylated in their cfDNA (P = 0.022; Figure 3(c)). This evidence concerns the gene RASSF1 and breast cancer.